Asia News
Filter News
Found 39,755 articles
-
The U.S. Securities and Exchange Commission has halted registrations of U.S. initial public offerings (IPOs) by Chinese companies.
-
Collaborating with Frazier Healthcare Partners, the team spun out a new company dubbed HilleVax to take Takeda’s norovirus vaccine into Phase 3 trials.
-
BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib) to Bendamustine Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
7/30/2021
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), today announced positive topline results from an interim analysis of the Phase 3 SEQUOIA trial comparing BRUKINSA® (zanubrutinib) to bendamustine and rituximab (B+R) in patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose tumor did not exhibit the deletion of chromosome 17p13.1 (del[17p])
-
Junshi Biosciences Announces Acceptance by NMPA of Supplemental New Drug Application for Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
7/30/2021
Junshi Biosciences (HKEX: 1877; SSE: 688180), announced today that the National Medical Products Administration (NMPA) of China has accepted its supplemental New Drug Application (sNDA) for toripalimab in combination with platinum-containing chemotherapy as the first-line treatment for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)
-
I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease
7/30/2021
I-Mab (the "Company") (Nasdaq: IMAB), today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) submission for Protollin, an investigational drug to treat Alzheimer's disease, enabling a Phase 1 clinical trial to be initiated.
-
Astellas and Minovia Therapeutics Announce Strategic Collaboration for Novel Mitochondrial Cell Therapy Programs
7/30/2021
Minovia Therapeutics, Ltd. (CEO; Natalie Yivgi-Ohana, Ph.D., “Minovia”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced a worldwide strategic collaboration and license agreement for the research, development, and commercialization of novel cell therapy programs for diseases caused by mitochondrial dysfunction.
-
ALK and Grandpharma team up to market the first adrenaline autoinjector in China
7/30/2021
ALK and the pharmaceutical company China Grand Pharmaceutical and Healthcare Holdings Limited (”Grandpharma”) today announced an exclusive licensing agreement that will see ALK’s AAI Jext® registered and launched in China, and will expand ALK's presence in the country.
-
Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued Pipeline Progress
7/30/2021
Takeda Pharmaceutical Company Limited announced financial results for the first quarter of fiscal year 2021.
-
Universe Pharmaceuticals INC to Announce Unaudited Financial Results for The First Six Months of Fiscal Year 2021 on August 2, 2021
7/30/2021
Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that it will release its unaudited financial results for the first six months of fiscal year 2021 ended March 31, 2021 on Monday, August 2, 2021 before the market opens.
-
Yiviva Wins 2 Top Awards at SAPA Investment Forum and Road Show for Innovative Systems Biology Approach to Treat Cancer
7/30/2021
Yiviva, a clinical-stage biotechnology company that uses a systems-biology approach to treat aging-associated diseases, won two top awards at the 4th annual Sino-American Pharmaceutical Professionals Association (SAPA) Investment Forum and Road Show.
-
Semglee was approved under the FDA’s 351(k) pathway, a biologics license application process. It ensures that the bio similarity is based on animal studies, clinical trials, and analytical studies.
-
Three major pharmaceutical and biotechnology companies announce the success of their respective funding rounds to support future efforts.
-
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations including Takeda, Origin Therapeutics, ERS Genomics and more.
-
Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues
7/29/2021
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and PeptiDream, Inc. (Tokyo Stock Exchange: 4587), announced today a license and collaboration agreement to discover and develop peptide-siRNA conjugates to create multiple opportunities to deliver RNAi therapeutics to tissues outside the liver.
-
Neukio Biotherapeutics completed its $40m Angel round financing, focusing on the development of iPSC-CAR-NK platform and assets.
7/29/2021
Neukio Biotherapeutics, a newly established company, recently announced the completion of its $40m Angel round of financing led by Lilly Asia Venture (LAV), with the participation of IDG Capital and Sherpa Investments.
-
Palisade Bio and Newsoara Announce Positive Topline Efficacy Results from Phase 2 Study of LB1148 Demonstrating Accelerated Return of Bowel Function After Gastrointestinal Surgery
7/29/2021
Palisade Bio, Inc. (Nasdaq: PALI) and co-development partner Newsoara today announced positive topline Phase 2 clinical trial data that LB1148 had a statistically significant (p=0.0008) effect in accelerating the return of bowel function in patients undergoing elective bowel resection surgery.
-
I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the Company up to US$40 Million
7/29/2021
I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced that its Board of Directors has authorized a new stock repurchase program.
-
Everest Medicines Receives Pediatric and Rare Severe Disease Priority Review Designation from Taiwan FDA for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
7/29/2021
Everest Medicines announced that the Taiwan Food and Drug Administration has granted Pediatric and Rare Severe Disease Priority Review Designation for sacituzumab govitecan-hziy, an investigational treatment for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one of them for metastatic disease.
-
HanAll Biopharma Reports Second Quarter 2021 Results
7/29/2021
HanAll Biopharma announced that the company had achieved sales of 23.4 billion won, operating profit of 1.6 billion won, and net profit of 3.3 billion won in the second quarter of 2021.
-
Daewoong Pharmaceutical Announces Camostat Achieving 50% Faster Recovery Time for Mild COVID-19 Patients Over Age of 50 in Topline Results from Phase 2B Clinical Trial
7/29/2021
Daewoong Pharmaceutical announced its phase 2B clinical trial topline results for Foistar, which is being developed as a treatment for COVID-19.